Noninvasive methodologies for measuring carcinogen expoure in humans, based on the use of urinary markers, are being developed and validated for use in molecular epidemiological studies. A range of3-alkyladenines can be determined in urine samples by an immunoafflnty puriflcation-GC/MS approach [3-methyladenine, 3-ethyladenine, 3-(2-hydroxyethyl)adenine, and 3-benzyladeninel. Using this method, recent results in human subjects suggest that urinary 3-alkyladenines are potentially usefl markers ofalkylating agent exposure, particularly where the backgrounds of such adducts are much lower than 3-methyladenine. Urinary excretion of S-benzylmercapturic acid has been studied in experimental animals as a marker ofexposure to benzylatingagents such as N-nitroso-methylbenzylamine. 3-Nitrotyrosine (NTyr) is formed in vivo in tissue or blood proteins after exposure to nitrosating and/or nitrating agents such as tetranitromethane. After turnover of proteins, NTyr is released and excreted in urine as metabolites 3-nitro-4-hydroxyphenylacetic aad and 3-nitro-4-hydroxyphenylacetic acid, which are determined by GC with a thermal energy analyzer. The sensitivity and specificit, combined with ease of use, of these noninvasive bimonitoring approaches means that they may be readily inorporated into molecular epidemiological studies in which qxpue to nitrosating and alkylating agents may be important risk factors.
Introduction
In the rapidly expanding field ofmolecular epidemiology, the precise determination of individual exposure to carcinogens is regarded as a desirable goal. It would, nevertheless, be a mistake to translate this objective into one of the determination of individual cancer risk [although this remains a popular idea (1) ].
In contrast, it is clear that groups of people at high risk of developing a particular cancer may be identified using molecular markers of carcinogen exposure. A number of methods are available to determine human exposure to carcinogens and are based on the idea that initiation, via formation of mutagenic lesions in DNA, is a crucial (but not sufficient) step in multistage carcinogenesis (2) . Thus, characteristic adducts can be determined in DNA extracted from a variety ofsources inducing target tissues (obtained during surgery or at necropsy), or from nucleated blood cells such as lymphocytes. This approach has unequivocally demonstrated human exposure to a range of agents arising from food [e.g., aflatoxin B1 (3)], occupation [e.g., benzo[aJpyrene (4) ], and lifestyle [e.g., tobacco smoking (5) ].
Blood protein adducts to these same exposures have been exploited as surrogate markers of DNA damage (3, 5) . All ofthese methods require tissue or blood samples which may limit the numbers of samples available for analysis. In addition, levels of adducts in nontarget tissues may not necessarily be good indicators oftarget tissue exposure or even ofwhole-body burden. It is from this standpoint that the idea of using noninvasive methods based on urinary analysis has been developed. Of the many types of DNA damage arising from carcinogen exposure, DNA alkylation has been extensively studied and biomonitoring methods based on this phenomenon form the main focus of this review.
As mentioned above, measures of human exposure to agents resulting in characteristic DNA damage are among the most important types of information to obtain, and it is crucial to show that any indirect method (such as urinary analysis) can give relevant information. Work ty Craddock and Magee (6) showed that exposure ofrats, whose DNA was labeled with 14C, to 3H-labeled dimethylnitrosamine (NDMA) resulted in urinary excretion of doubly labeled N7-methylguanine (N7-MeGua). It was shown, unambiguously, that most of this urinary adduct was derived from liver, which is the major target organ for NDMA carcinogenesis. More recently, Gombar et al. (7) showed that coadministration of [ able at doses where in situ methylation was undetectable due to practical problems in obtaining sufficient DNA from liver for adduct analysis at low levels of modification (whereas urinary N7-MeGua was derived from the whole organ and possibly other sites). Bennett et al. (8) showed in rats that urinary excretion of aflatoxin B,-guanine adduct correlated well with levels of adduct in the liver (which is the target organ). These results suggested that determination of excreted DNA adducts (or alkylpurines) that arise as a consequence of DNA repair mediated by DNA glycosylases (9) form the basis of noninvasive methods for determining of DNA damage following human exposure to alkylating carcinogens.
In a broader context, it may be useful to obtain information on the whole-body burden of alkylating agents and/or precursors. Many alkylating carcinogens react with glutathione (GSH) in vivo and give rise to mercapturic acids (MAs), which in many cases represent the major urinary metabolite (10) . SN2 alkylating agents (such as alkyl halides, epoxides, and alkylsulfonates) can give up to 50% of the administered dose as MAs, which has led to much interest in the use of MAs as urinary markers of exposure to SN2 alkylating agents (11) . In contrast,SN1 alkylating agents such as alkyldiazonium ions (the presumed active metabolites of N-alkyl-N-nitroso compounds) tend to give much lower yields although fewer of these compounds have been studied in this respect [e.g., dimethylnitrosamine (12) , Nnitroso-di-n-butylamine (13) , and N-nitroso-N-methylbenzyl-
From the point ofview of human biomonitoring to alkylating carcinogens, mercapturic acids offer the possibility of noninvasively measuring the biological effective dose of alkylating species. There are indications, however, that the use of mercapturic acids must be approached with care. Many studies in humans have made use of methods to determine total urinary thioethers (which include MAs), and in many cases no differences could be detected between controls and exposed subjects with wide variation in individual levels (11) . Aringer and Lidums (14) have also drawn attention to the problems of dietary confounding in the total urinary thioether method. As a consequence, it has been recognized that the determination of individual mercapturic acids is not only desirable because of sensitivity, but also adds to the specificity of the method, as in the case of acrylonitrile (15) , benzene (16) and ethylene oxide (17) . Individual MAs can be determined by a number of methods including GC (15) , HPLC-electrochemical detection (18) , HPLCfluorescence of derivatives (17), and GC-MS (19) .
Endogenous formation of N-nitroso compounds has been
shown to occur in humans, using N-nitrosamino acids excreted in urine as a marker (20, 21) . Carcinogenic N-nitroso compounds appear to be formed mainly in the stomach by the reaction of certain nitrogen-containing compounds with nitrite under acidic conditions. However, endogenous nitrosation may also occur in other organs such as the lung (22) and skin (23) after exposure to oxides of nitrogen and in inflamed or infected tissues by activated macrophages and bacteria (24, 25) , although such reac- tions have not yet been demonstrated to occur in tissues in vivo.
We are currently developing and validating noninvasive methodologies, based on the use of urinary markers, for eventual use in human biomonitoring studies. This approach is divided into three parts: a) an assessment of DNA damage by measurement of excreted alkylpurines b) the determination of specific urinary mercapturic acids, and c) the evaluation of precursors, e.g., endogenous nitrosation potential using 3-nitrotyrosine metabolites. Recent results in these areas are reviewed in this paper.
Urinary Alkylpurines
Alkylation at N-3 of adenine is a major route of DNA-adduct formation for many alkylating carcinogens (26) . The resulting 3-alkyldeoxyadenosines are unstable and rapidly depurinate either spontaneously or via the action of specific DNA glycosylases to give the corresponding 3-alkyladenines (3-alkAde) (9) .
We have recently shown that 3-methyladenine (3-MeAde) can be rapidly quantitated in human urine by immunochemical and/or GC-MS methods (27, 28) . In a recent study of cancer patients receiving methylnitrosourea (MNU, at a total single dose of 300 or 600 mg) as part ofa combination chemotherapy, 24 cross-reacts with a range of 3-alkyladenines (29), to protein ASepharose CL-4B. Columns were prepared in a similar way to that described recently (28) . The full details of the preparation and characterization of these immunoaffinity columns will be described elsewhere (Prewvst et al., manuscript in preparation). Thus far, analytical procedures for 3-MeAde, 3-ethyladenine (3-EtAde), 3-(2-hydroxyethyl)adenine (3-HOEtAde), and 3-benzyladenine (3-BzAde) have been developed. Deuterated internal standards (d3-3-MeAde, d5-3-EtAde, d4-3-HOEtAde, and d7-3-BzAde) were synthesized by standard methods and were routinely added to urine samples (5 mL) before immunoaffinity purification. Selected ion monitoring using a low resolution quadruple GC-MS system (Hewlett Packard 5970A) was used to quantitate the 3-alkAde. A representative GC-MS trace of four 3-alkyladenines with corresponding internal standards is shown in Figure 2 . Using this approach a number of studies have been carried out, and the main conclusions are summarized below: 
Specific Mercapturic Acids
Measures of alkylating agent exposure based on total urinary mercapturic acids are often confounded by the presence of natural background levels. In contrast, the determination of individual mercapturic acids should be characteristic of a particular exposure.
In view of interest in the role of N-nitroso-N-methylbenzylamine (NMBzA) as a possible etiological agent in esophageal cancer in China, the utility of S-benzylmercapturic acid (SBzMA) as a marker ofbenzylation was investigated. The excretion of SBzMA in the urine ofrats treated with NMBzA was determined by GC-MS using d7-SBzMA as an intenal standard.
The amount ofurinary SBzMA varied with the dose ofNMBzA (up to 5 mg/kg) and with rat strain. For the three strains investigated, most of a 2.5 mg/kg dose of SBzMA was excreted within 24 hr. Comparison ofthe levels of SBzMA excreted by rats treated with equivalent doses of either NMBzA or benzaldehyde indicates that urinary SBzMA is derived mainly from benzylating species resulting from the hydroxylation of the methyl group of NMBzA (30) .
In view of the success of immunochemical methods, in particular, immunoaffinity purification, in the area ofurinary DNA adducts, current work is aimed at preparing antibodies against mercapturic acids either individually (e.g., SBzMA) or as a group.
Endogenous Nitrosation 3-Nitrotyrosine (NTyr) in tissue or blood proteins was evaluated as a possible exposure marker for exogenous and endogenous nitrosating or nitrating agents. A sensitive and selective method for analyzing NTyr by gas chromatography with a thermal energy analyzer (GC-TEA) was developed. Using this method, kinetic studies were carried out. It was found that free and protein-bound tyrosine residues easily react with nitrating/nitrosating agents to yield NTyr. NTyr formation in vivo showed a dose dependent increase in NTyr in both plasma proteins and hemoglobin obtained from rats 24 hr after IP injection of various doses (0.5-2.5 ymole/rat) oftetranitromethane. Major urinary metabolites of NTyr, given orally to rats, were isolated and identified by GC-MS as 3-nitro-4-hydroxyphenylacetic acid (NHPA) and 3-nitro-4-hydroxyphenyllactic acid (NHPL). About 44 and 5 % of the oral dose of NTyr (100 lsg/rat) was excreted as NHPA and NHPL, respectively. Eleven 24-hr human urine samples were analyzed for NHPA by GC-TEA after ethyl acetate extraction and HPLC purification: quantities ranging from 0 to 7.9 Ag/24 hr (mean ± SD, 2.8 ± 2.3, n = 11) were detected (detection limit 0.2 ug/L). Thus, NTyr in proteins or its metabolites in urine can be readily analyzed by GC-TEA as a marker for endogenous nitrosation and nitration (31) .
Initial attempts to prepare antibodies to NTyr in order to prepare immunoaffinity columns were not particularly successful, and an approach using novel haptenic forms of NTyr is currently being pursued.
Discussion
The methods described here are undergoing continuous refinement, particularly in the area of specificity, as well as being thoroughly validated. A criticism that may be leveled against the use of urinary markers such as excreted adducts is that they may be derived from total nucleic acid alkylation (i.e., DNA Each ofthe three approaches described in this paper have the potential to convey information about various aspects of human exposure to alkylating carcinogens. It is clear, however, that a combination of these approaches is more powerful than when they are applied individually. For example, DNA adducts arising from preformed tobacco-specific nitrosamines can be readily determined using urinary adducts, but it will be interesting, in addition, to assess the role of endogenous nitrosation of tobacco alkaloids, using 3-nitrotyrosine, as this may be a major contributing pathway.
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